Johnson & Johnson Expands Procedure-Based Offerings with Bladder Cancer and Vision Advances

Johnson & Johnson reported promising Phase 1 results for an extended release erdafitinib delivery system in non-muscle invasive bladder cancer and received FDA approval for its TECNIS PureSee intraocular lens for cataract surgery. These updates highlight the company's pipeline progress in large, long-term health needs such as cancer and age-related vision loss. The real test will come from larger studies, physician uptake, and how these offerings fit into treatment guidelines and cataract surgery practice over time.